Williston (OTCMKTS:WHCA) vs. Belite Bio (NASDAQ:BLTE) Critical Analysis

Belite Bio (NASDAQ:BLTE) and Williston (OTCMKTS:WHCA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, earnings, institutional ownership, risk, analyst recommendations and valuation.

Institutional and Insider Ownership

0.5% of Belite Bio shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Belite Bio and Williston”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61 million	($2.53)	-59.20
Williston	N/A	N/A	N/A	N/A	N/A

Volatility and Risk

Belite Bio has a beta of -1.24, suggesting that its share price is 224% less volatile than the S&P 500. Comparatively, Williston has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Belite Bio and Williston, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1	1	6	0	2.63
Williston	0	0	0	0	0.00

Belite Bio presently has a consensus price target of $203.00, suggesting a potential upside of 35.53%. Given Belite Bio’s stronger consensus rating and higher probable upside, research analysts clearly believe Belite Bio is more favorable than Williston.

Profitability

This table compares Belite Bio and Williston’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
Williston	N/A	N/A	N/A

Summary

Belite Bio beats Williston on 5 of the 8 factors compared between the two stocks.

About Belite Bio

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

About Williston

Williston Holding Company, Inc. owns and operates restaurants. The company was incorporated in 2012 and is based in Eden Prairie, Minnesota.